Viridian Therapeutics reveals promising long-term results for veligrotug in treating thyroid eye disease, highlighting its ...

UNITY Biotechnology reveals promising 36-week results for UBX1325 in treating diabetic macular edema, showing non-inferiority ...

Participant Characteristics: Blinded baseline data aligns with the target population identified in the Phase 2b UC study. Safety Monitoring: No new safety signals observed in the latest Data ...

Upadacitinib shows sustained efficacy and consistent safety for moderate to severe ulcerative colitis in long-term trials and ...

Veru Inc. updates on its Phase 2b clinical trials, expecting safety data and discussing plans for Phase 3 with the FDA. Veru Inc. reported its financial results for the second quarter of fiscal ...